SEC filings and other documents

Breakthrough approvals and robust launches drive growth, with a deep pipeline advancing in CNS and metabolic diseases.

Strong FDA approvals and robust launches drive growth, with pipeline and market leadership advancing.

FDA approved ZANVASTRO for Alexander disease, enabling broad access and rapid commercial launch.

Strong revenue growth and successful product launches position the company for continued expansion.

TRYNGOLZA approved as first sHTG therapy, showing 72% triglyceride and 91% pancreatitis event reduction.

TRYNGOLZA and pipeline launches drive growth, targeting $3B+ peak sales and cash breakeven by 2028.

Poised for $7B+ peak revenue and break-even cash flow by 2028, driven by pipeline and launches.

Multiple late-stage readouts, new launches, and strong demand drive growth and market expansion.

Strong commercial growth and a robust pipeline position the company for sustained expansion.

Q1 revenue surged 87% year-over-year, with raised 2026 guidance and strong launch momentum.

Tau-targeting and Angelman programs advance with robust data, innovative delivery, and key readouts ahead.

Blockbuster launches and major phase III readouts set to drive growth and market expansion in 2024.

TRYNGOLZA and SHTG launches drive growth, with innovation and partnerships fueling future opportunities.

Major launches, pivotal data, and strategic pricing set the stage for transformative growth in 2026.

Priority review for olezarsen and robust late-stage pipeline drive strong growth outlook.

2025 revenue surged 34% to $944M, with robust launches and strong royalty streams.